Heath Lukatch, PhD is a Partner at TPG Capital. He is a member of the Board of Directors for Adynxx, Engage Therapeutics (Chairman), Flexion Therapeutics (Nasdaq FLXN), Halo Neuroscience, Inogen (Nasdaq INGN) (Chairman), Satsuma Pharma (Chairman), SutroVax and ViewPoint Therapeutics.
Before joining TPG in 2015, Dr. Lukatch was a Partner at Novo Ventures (U.S.), where he helped establish Novo Ventures’ San Francisco office. During his 9 years at Novo, Dr. Lukatch served as Chairman of Cianna Medical, Inogen (Nasdaq: INGN), NTP and Spinifex Pharmaceuticals (acquired by Novartis in 2015), and he served as a board member at Amira Pharmaceuticals (acquired by BMS in 2011), AnaptysBio (Nasdaq: ANAB), Elevation Pharmaceuticals (acquired by Sunovion in 2012), Flexion Therapeutics (Nasdaq: FLXN), FoldRx Pharmaceuticals (acquired by Pfizer in 2010), InSound Medical (acquired by Sonova in 2010), Nora Therapeutics and Synosia Therapeutics (acquired by BioTie in 2011), and he was also a board observer at Alios BioPharma (acquired by J&J in 2014).
Prior to joining Novo Ventures (U.S.), Dr. Lukatch was a Managing Director responsible for biotechnology venture investments at Piper Jaffray Ventures and SightLine Partners, where his investments included Dynavax (Nasdaq: DVAX) and Fluidigm (Nasdaq: FLDM). Before Piper Jaffray Ventures, Dr. Lukatch worked as a strategy consultant with McKinsey & Company, where he was a leader in McKinsey’s biotechnology practice. Dr. Lukatch also served as co‐founder and CEO of AutoMate Scientific, a biotechnology instrumentation company, and he has held scientific positions with Chiron, Roche Bioscience and Cetus, doing molecular biology, electrophysiology and protein chemistry, respectively.
Dr. Lukatch received his PhD in Neuroscience from Stanford University where he was a DOD USAF Fellow and his BA with high honors in Biochemistry from the University of California at Berkeley.
President, Chief Executive Officer and Founder
Greg Mayes founded Engage Therapeutics in 2017 after more than 20 years of leadership roles in the biopharmaceutical industry. His personal experience caring for his teenage son with epilepsy drives his passion in developing Staccato Alprazolam, an investigational seizure rescue treatment that could abort ongoing seizures. Greg is dedicated to leveraging his drug development experience and working with key opinion leaders (KOLs) to identify new therapeutic options for patients affected by epilepsy.
Previously, Greg played an integral role in the growth of Advaxis Immunotherapies, a Princeton, N.J., based biotech company developing immuno-oncology therapies for patients with hard-to-treat cancers through its bacterial vector system, Lm Technology™. As its chief operating officer, he was instrumental in helping to secure more than $200 million in funding and in identifying and negotiating partnerships with companies such as Amgen, AstraZeneca and Merck & Co., Inc. Greg also served as a president of Unigene Laboratories, Inc.
Greg also served as ImClone’s general counsel, playing a key role in managing multiple clinical and regulatory activities that led to the 2008 acquisition by Eli Lilly for $6.5 billion. Earlier in his career, Greg was responsible for providing legal advice to the AstraZeneca oncology franchise as senior counsel and he started his biopharma legal career at the national law firm of Morgan Lewis. Greg holds a BS from Syracuse University and a JD from Temple University School of Law.
Gerry Brunk is a Managing Director at Lumira Ventures, a North American healthcare venture capital firm. Since joining Lumira Ventures in 2002 he has invested in and served on the boards of directors of over 20 life science companies, including Pharmasset (acquired by Gilead Sciences), MAKO Surgical (acquired by Stryker), Corvia Medical, Celtaxsys, KAI Pharmaceuticals (acquired by Amgen), Endotronix, BAROnova, Targanta Therapeutics (acquired by The Medicines Company) and Cardiac Dimensions.
Before joining Lumira Ventures, Gerry was an entrepreneur who co-founded and served in a variety of management and board capacities at venture capital-funded companies in the pharmacy benefit management, senior living, and technology transfer sectors. As an Engagement Manager in the healthcare practice of The Boston Consulting Group, he advised pharmaceutical firms on strategic issues involving portfolio management, R&D productivity, new product launches, reimbursement and acquisitions. Gerry began his career as a member of the investment banking group of Credit Suisse First Boston where his clients included public and private healthcare companies.
Gerry holds an MBA from Stanford University Graduate School of Business and a BA from the University of Virginia, where he studied biology and economics. He serves on the board of Southeast BIO, the oversight committee of the Wallace H. Coulter Center for Translational Research at the University of Miami, the review board of the Ivy Foundation Biomedical Innovation Fund at the University of Virginia, and as a mentor for the Canadian Technology Accelerator in Boston and for the Stanford University Biodesign program.
Stephen D. Collins
A career R&D leader, Steve Collins has led or supported clinical programs across a wide range of indications that have resulted in over a dozen approved drugs. He currently serves as Chairman of Xalud Therapeutics, a gene therapy company in late pre-clinical stage and President and CEO of Biscayne Neurotherapeutics, a small molecule clinical-stage company with focus on CNS applications. He was recently the CEO and President of NeuroTherapeutics Pharma, an early stage biotechnology company where he raised $42 million to advance novel therapeutics for CNS.
Prior to NeuroTherapeutics, he was Chief Scientific Officer & VP for Clinical Affairs of Ovation Pharmaceuticals, an oncology and CNS-focused biopharmaceutical company acquired by Lundbeck A/S for $963 million. Steve established the company’s R&D group and built it into a team of over 60 professionals. He was also responsible for establishing the safety and post-marketing research groups and leading all scientific and medical in-licensing activities. His R&D team performed the preclinical and clinical work for four development programs resulting in two approved NDAs as well as managed in-market product life cycles for all oncology and hematology products.
Orrin Devinsky is Professor of Neurology, Neurosurgery, and Psychiatry at the NYU School of Medicine, where he directs the Epilepsy Center. He also directs the Saint Barnabas Institute of Neurology. His epilepsy research includes cannabidiol, autism, clinical-genetic correlations, healthful behavioral changes, sudden death, therapeutic electrical stimulation, quality-of-life, cognitive and behavioral issues, and surgical therapy. He is the Principal Investigator for the North American SUDEP Registry and for the SUDC Registry and Research Collaborative.
He is on the Executive Committee of the SUDEP Institute and Scientific Advisory Boards of the Epilepsy Foundation, Dup15q Alliance, Tuberous Sclerosis Association, KCNQ2 Cure Alliance Foundation, and Loulou Foundation CDKL5 Program of Excellence. He serves as the lead investigator for the Epidiolex Dravet and Lennox-Gastaut studies. He founded Finding A Cure for Epilepsy and Seizures (FACES) and co-founded the Epilepsy Therapy Project and epilepsy.com. Outside interests include behavioral neurology, evolutionary biology and history of neuroscience.
Warren B. Lammert III is Chief Investment Officer and Founding Partner of Granite Point Capital. He previously served as Portfolio Manager of the Janus Mercury Fund from its inception in 1993 until March 2003.
Warren is a former Chairman of the Epilepsy Foundation of America. He also serves on the Board of Directors of Biscayne NeuroTherapeutics, Inc., TevarD Biosciences, and the Advisory Board of FACES (Finding a Cure for Epilepsy and Seizures) at New York University.
Warren received his BA in Economics from Yale University and graduated with Distinction from the London School of Economics with an MSc in Economic History. He has also earned the right to use the Chartered Financial Analyst designation.